Rapamycin, a relatively selective inhibitor for mTORC1 [349,350], and its analogues have demonstrated benefits as autophagy enhancers that decrease Aβ and Tau levels, ameliorate neuropathology, and attenuate cognitive deficits in the animal models of AD [90,92,351-354]. This evidence concerns the gene MAPT and Alzheimer disease.